Artal Group S.A.

In its 13F for Q1 2026 (holdings as of March 31, 2026, filed May 14, 2026), Artal Group S.A. reported 2 stock positions worth $1.0 billion. Its top holding was Cava (CAVA) at 76.1% of the portfolio, followed by Lexicon Pharmaceuticals (LXRX, 23.9%). Compared with Q4 2025, it added to 1. The biggest buy was Lexicon Pharmaceuticals (LXRX, shares +14%).

Most Recent 13F
Q2 2026
Location
LUXEMBOURG, N4
CIK
0001053906
Portfolio Value
$1.0B (Q1 2026)
SEC Filing
0001053906-26-000006 ↗ filed May 14, 2026

Holdings Value

0$1.0B$2.0B$3.0B$4.0B Q1 2024: $3.9B Q1 2024 Q2 2024: $3.9B Q2 2024 Q3 2024: $2.4B Q3 2024 Q4 2024: $1.2B Q4 2024 Q1 2025: $884.2M Q1 2025 Q2 2025: $930.2M Q2 2025 Q3 2025: $758.2M Q3 2025 Q4 2025: $714.6M Q4 2025 Q1 2026: $1.0B $1.0B Q1 2026 Q2 2026: $931.1M Q2 2026

Holdings 2 stocks · $1.0B
CAVA Cava Group Inc. 76.11% 9,507,990 $769.2M No change
LXRX Lexicon Pharmaceuticals Inc. 23.89% 154,734,327 $241.4M Add +13.6%

Portfolio Sells Q4 2025 → Q1 2026
None this quarter.

Portfolio Buys Q4 2025 → Q1 2026
LXRX Lexicon Pharmaceuticals Inc. Add +13.6% 23.89% +1.97

All Filings

QuarterPositions13F Reported ValueTop Holdings
Q2 2026 2$931.1MCAVA, LXRX
Q1 2026 2$1.0BCAVA, LXRX
Q4 2025 2$714.6MCAVA, LXRX
Q3 2025 2$758.2MCAVA, LXRX
Q2 2025 2$930.2MCAVA, LXRX
Q1 2025 2$884.2MCAVA, LXRX
Q4 2024 2$1.2BCAVA, LXRX
Q3 2024 2$2.4BCAVA, LXRX
Q2 2024 108$3.9BCAVA, LXRX, SRRK, KYMR, MORF
Q1 2024Amended 107$3.9BCAVA, LXRX, SRRK, KYMR, ARWR